<h3>Objectives:</h3> USC and its ovarian counterpart (OSC), the most lethal gynecologic malignancies, are resistant to current therapies. We noted that the highly annotated USC-derived cell line ARK1 lacks expression of collagen type III (COL3), the master organizer of VWC deposition during angiogenesis as evidenced by the COL3-deficient vascular Ehlers-Danlos Syndrome (OMIM 130050). In USC, vascular COL3 may therefore originate from interstitial cells via MRMC. We hypothesized ARK1 to express mediators of MRMC. Our objective was to test this hypothesis in standard culture (SC) and in angiogenic overdrive (AO) condition, using both gene expression profiles for anti-cancer drug discovery. Our AO protocol employs FDA-approved medicines that maximally push <i>and</i> maximally brake angiogenesis by inhibiting ketoglutarate-utilizing protein hydroxylases (KPHs), e.g. the enzymes forming peptide-bound hydroxylproline. We reported that such medicines advance angiogenesis via activated molecular oxygen sensing <i>yet at the same time</i> inhibit deposition of the stable collagenous matrix required for angiogenesis, thus trapping cancer cells between ‘hammer and anvil'. <h3>Methods:</h3> Cell culture, repeat RNA-seq, antigen-specific protein detection. <h3>Results:</h3> ARK1-SC expressed an extraordinary array of angiogenesis-relevant genes that encode a) the mediators of MRMC (connective tissue growth factor [CTGF], the suite of fibroblast growth factors [FGFs, FGFR1-4, FGFRL1, FRS2-3, FGFBP1] and ligands signaling over a few cell diameters [e.g. WNT5B]; b) all elemental VWCs except COL3 (49 collagen/laminin/fibrillin chains; the entire elastin suite [ELN, LOX, LOXL1-4, EMILIN1-3, MMRN2, FBLN5] and proteoglycans [e.g. HSPG2, VCAN]; c) angiogenic factors, from capillary tube formation to branching morphology (e.g. all 6 subunits of the hypoxia inducible factors [HIF1-3]; the suite of vascular endothelial growth factors [VEGFA-C, FIGF, FLT1, KDR, FLT4]; NRP1; HBEGF; even the beta-2 adrenergic receptor ADRB2]; d) the complete set of 41 KPHs required for physiological function in a-c. After 48 hours at clinical concentrations of the KPH-inhibitory medicine deferiprone, ARK1-AO accumulated underhydroxylated collagens intracellularly, indicating blockade of collagen secretion due to triple helix collapse and mis-folding. Simultaneously, expression of CTGF increased 16.1-fold, FGF2 2.5-fold, FGF1 14.5-fold, and FGF5 23.8-fold over control ARK1-SC (RPKM-based FDR p: 10<sup>-2</sup> to 10<sup>-6</sup>) whereas expression of their corresponding receptors remained unchanged and COL3 expression defective. VEGFA/VEGFB expression fell by almost 50%, with likewise unchanged receptor expression. HBEGF expression rose 9-fold (FDR p<10<sup>-6</sup>), suggesting it to be the major angiogenic mediator of MRMC. Further indicating self-contradictory signaling conflict induced by KPH inhibition, expression of WNT5B rose 5.5-fold, yet of its antagonist DKK1 46-fold (FDR p=10<sup>-5</sup>). <h3>Conclusions:</h3> ARK1 is a genetically defined USC model to interrogate the targeted disruption of MRMC. The pioneer KPH inhibitory medicine deferiprone exploits the asymmetry between KPH-stabilized matrix proteins (e.g. collagens) and KPH-destabilized oxygen sensors (e.g. HIFs) to disrupt both and in this process, reveal the genetic circuitry for matrix recruitment and angiogenesis. We identify CTGF, FGFs, and HBEGF as key factors that enroll interstitial cells for procurement of tumor perfusion. We anticipate therapeutic value of current CTGF/FGFs/HBEGF antagonists in USC (and OSC).
Read full abstract